Madison Mills goes over some of the top stories on this segment of Market Minute. eToro (ETTO.PVT) is skyrocketing after making its debut on the Nasdaq Composite (^IXIC). Exelixis (EXEL) is soaring after the company beat first quarter estimates and boosted its full-year revenue forecast. Septerna (SEPN) struck a deal with Novo Nordisk (NVO) for $2.2 billion for obesity medications. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. Video Transcript 00:00 Speaker A It's time for Yahoo! Finance's market minute. U.S. stocks looking for footing after the S&P 500 erased its year-to-date losses. Meantime, eToro making its public debut on the Nasdaq. The trading platform opening trade at $69.69. That's above the IPO price of $52. The company making its debut after delaying its IPO plans following the president's tariff announcements in April. Exelixis shares rising as the company boosts its revenue forecast for the year. The drug maker also beating earnings and revenue estimates for the first quarter. Cytokinetics inking a $2.2 billion deal with Novo Nordisk. The two companies to collaborate on oral small molecule medicines for obesity. The deal includes more than $200 million in upfront and near-term milestone payments to Cytokinetics. That's your Yahoo! Finance market minute. For more on what's trending on Yahoo! Finance, you can scan the QR code below to track the best and worst performing stocks. Related Videos 01:00 Oklo moves higher, American Eagle pulls guidance, Reddit surges Yahoo Finance Video • 1 hour ago 40:17 Home price inflation, gifting stocks, Congressional tax bill: Wealth Yahoo Finance Video • 1 hour ago 01:44 EToro Soars 42% After $620 Million Upsized IPO Bloomberg • 1 hour ago 02:51 Morgan Stanley's Slimmon Says He's More Cautious on Stocks Bloomberg • 2 hours ago View Comments
eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...